Trials to watch: Four ALS drugs to keep an eye on

It has been a turbulent few weeks for patients with amyotrophic lateral sclerosis (ALS) after Amylyx Pharmaceuticals pulled its lead drug Relyvrio from the market after a Phase III trial did not meet its primary endpoint.

The drug was pegged to be revolutionary for patients as it was said to slow disease progression, however Phase III data showed no difference between the candidate and placebo.

Despite this setback, chief research officer at the Muscular Dystrophy Association, Dr Sharon Hesterlee, says that there are plenty of novel candidates in the pipeline. “The good news is the pipeline is healthy for ALS, which is important, especially given what has happened with Amylyx’s drug which was disappointing for everyone,” Hesterlee explains.